ThioTEPA

Jump to: navigation, search
180px
ThioTEPA
Systematic (IUPAC) name
N,N ' N '-triethylenethiophosphoramide
Identifiers
CAS number 52-24-4
ATC code L01AC01
PubChem 5453
Chemical data
Formula C6H12N3PS 
Mol. mass 189.219 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism Hepatic (CYP2B6, CYP2C11)
Half life 2.4 hours
15-18 hours (metabolites)
Excretion Renal
Therapeutic considerations
Pregnancy cat.

D(AU) D(US)

Legal status

POM(UK) -only(US)

Routes IV, intracavitary, intravesical

WikiDoc Resources for ThioTEPA

Articles

Most recent articles on ThioTEPA

Most cited articles on ThioTEPA

Review articles on ThioTEPA

Articles on ThioTEPA in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on ThioTEPA

Images of ThioTEPA

Photos of ThioTEPA

Podcasts & MP3s on ThioTEPA

Videos on ThioTEPA

Evidence Based Medicine

Cochrane Collaboration on ThioTEPA

Bandolier on ThioTEPA

TRIP on ThioTEPA

Clinical Trials

Ongoing Trials on ThioTEPA at Clinical Trials.gov

Trial results on ThioTEPA

Clinical Trials on ThioTEPA at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on ThioTEPA

NICE Guidance on ThioTEPA

NHS PRODIGY Guidance

FDA on ThioTEPA

CDC on ThioTEPA

Books

Books on ThioTEPA

News

ThioTEPA in the news

Be alerted to news on ThioTEPA

News trends on ThioTEPA

Commentary

Blogs on ThioTEPA

Definitions

Definitions of ThioTEPA

Patient Resources / Community

Patient resources on ThioTEPA

Discussion groups on ThioTEPA

Patient Handouts on ThioTEPA

Directions to Hospitals Treating ThioTEPA

Risk calculators and risk factors for ThioTEPA

Healthcare Provider Resources

Symptoms of ThioTEPA

Causes & Risk Factors for ThioTEPA

Diagnostic studies for ThioTEPA

Treatment of ThioTEPA

Continuing Medical Education (CME)

CME Programs on ThioTEPA

International

ThioTEPA en Espanol

ThioTEPA en Francais

Business

ThioTEPA in the Marketplace

Patents on ThioTEPA

Experimental / Informatics

List of terms related to ThioTEPA


Overview

N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

References

  • Sykes M; et al. (1953). "Clinical Studies of triethylenephosphoramide compounds with nitrogen mustard-like activity". Cancer. 6: 142–48. 
  • Maanen MJ, Smeets CJ, Beijnen JH (2000). "Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA)". Cancer Treat Rev. 26 (4): 257–68. PMID 10913381. 

de:Thiotepa



Linked-in.jpg